|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Paget's Disease of Bone
This disorder of bone metabolism results in slow enlargement of the affected bone, and deformities that sometimes produce severe pain and/or disfigurement. The abnormal bone may press on nerves and interfere with joint function. The cause is unknown.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Paget’s Disease Study CZOL446K2401
The purpose of this clinical trial is to find out if educating study investigators and participants effect of investigator and patient education on calcium and vitamin D supplementation can manage the potential for hypocalcemia (calcium deficiency) following the administration of a study drug injection in participants with Paget's disease of bone. The study drug has been approved by the US Food and Drug Administration (FDA) for the treatment of people with Paget's Disease.
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center about 2-3 times over a maximum of 1 month. Protocol Number: CZOL446K2401 |